icon
icon
icon
icon
Upgrade
icon

Novartis (NVS.US) raised its full-year earnings guidance again after Entresto and Kesimpta exceeded expectations in the first quarter.

AInvestThursday, Jul 18, 2024 4:10 am ET
1min read

Thanks to an increase in the number of prescriptions for Entresto, a drug for the treatment of heart failure, and Kesimpta, a drug for the treatment of multiple sclerosis, among others, Novartis (NVS.US) reported better-than-expected second-quarter results and raised its 2024 earnings forecast for the second time.

Novartis reported second-quarter revenue of $12.512 billion, up 9% year-on-year; net income of $3.246 billion, up 43% year-on-year; and earnings per share of $1.60, up from $1.09 a year earlier.

Adjusted operating profit was $4.953 billion, up 17% year-on-year, beating the consensus estimate of $4.6 billion; core earnings per share were $1.97, up from $1.69 a year earlier.

Novartis said it expected full-year adjusted operating profit to grow by a “mid-to-high double-digit” percentage, up from its previous forecast of a “low double-digit to mid-high double-digit” percentage.

The company’s sales of Entresto, Kesimpta and Cosentyx, an anti-inflammatory drug that has been approved for new uses, exceeded market expectations, according to the earnings statement.

The group, which has cut jobs and spun off its generic-drug business Sandoz, despite losing US patent protection on its blockbuster drug Entresto and Promacta, a drug for the treatment of blood platelet deficiency, next year, has confirmed its growth target for the medium term.

The company said it hoped to achieve $4bn annual sales for drugs such as Kesimpta, which had about $800m of revenue in the quarter.

Novartis also sees Leqvio, a cholesterol-lowering drug, as a potential blockbuster, with sales more than doubling to $182m in the second quarter.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.